Vasoplegic Shock treated with Methylene Blue complicated by Severe Serotonin Syndrome. by Chan, Betty S. et al.
Vasoplegic Shock treated with Methylene Blue complicated by Severe Serotonin Syndrome. 
 
Authors 
 
Betty S. Chan(1) PhD, FACEM 
 
Therese Becker(1) MBBS, FACEM 
 
Angela L. Chiew(1) MBBS, FACEM 
 
Ahmed M. Abdalla (2), PhD 
 
Tom A. Robertson (2), PhD. 
 
Xin Liu(3), PhD. 
 
Michael S. Roberts (2,3) DSc 
 
Nicholas A. Buckley(4) MD, FRACP. 
 
1. Clinical Toxicology Unit & Emergency Medicine, Prince of Wales Hospital, Sydney, 
New South Wales, Australia. 
2. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, 
Australia. 
3. Therapeutics Research Centre, Diamantina Institute, The University of Queensland, 
Translational Research Institute, Brisbane, Australia. 
4. Dept of Clinical Pharmacology, University of Sydney, Sydney, New South Wales, 
Australia. 
 
Word count: 1,560 
 
Corresponding author: Betty Chan, e-mail: betty.chan1@health.nsw.gov.au, Tel: 
61439601068, Fax: 61280160868 
 
There is no financial support used for the study. 
 
There is no conflict of interest to report. 
 
This case report was presented as a poster at the 37th International Congress of the 
European Association of Poison Centres and Clinical Toxicologists EAPCCT in Basel, May 
2017. 
 
Key words: Methylene blue, vasoplegic shock, vasodilator, dihydropyridine poisoning, 
overdose, serotonin syndrome. 
 
Acknowledgment: The authors would like to thank Ms Lorraine Mackenzie for her assistance 
in the analysis of the methylene blue samples. 
 
Abstract 
 
Introduction: 
 
Management of severe vasoplegic shock in overdose can be very challenging. We describe 
a case of severe refractory vasodilatory shock in poisoning where methylene blue (MB) was 
used with success. 
 
Case Report. 
 
A 70kg 15-year-old male presented 1.5 hours post ingestion of a large polypharmacy 
overdose of quetiapine slow release 1.5g, quetiapine immediate release 12g, desvenlafaxine 
slow release 5.6g, venlafaxine 1050mg, amlodipine 290mg, ramipril 100mg, fluoxetine 
560mg, promethazine 500mg and an unknown amount of lithium. He developed severe 
vasoplegic shock that was resistant to maximal doses of noradrenaline and vasopressin. 
MB was administered 6.5 hour post ingestion. Within 1 hour there was an improvement in 
his haemodynamic status and reduction of catecholamine requirements. Twelve hours post 
ingestion, he developed severe serotonin syndrome that lasted 5 days as a result of 
interaction between MB, a reversible monoamine oxidase inhibitor, and the antidepressants 
taken in overdose. MB had a calculated half-life of 38 hours. 
 
Conclusion 
 
MB is a useful second or third line strategy for severe drug induced vasodilatory shock, and 
may be potentially life-saving. Conversely, physicians should be aware that it can interact 
with other drugs and cause life-threatening serotonin syndrome. Lower doses or shorter 
durations may be wise in patients at risk of this interaction. 
 
Introduction: 
 
Methylene blue has been used for the treatment of vasoplegic shock. Case Report: We report a 15- 
year-old male with a massive overdose of quetiapine, amlodipine, ramipril, venlafaxine, 
desvenlafaxine and fluoxetine, resulting in vasopressor resistant vasoplegic shock, successfully 
managed with methylene blue(MB) but was complicated by severe prolonged serotonin 
syndrome(SS). MB was administered 6.5 hour post ingestion. Within 1 hour there was an 
improvement in his haemodynamic status and reduction of catecholamine requirements. Twelve 
hours post ingestion, he developed severe SS that lasted 5 days as a result of interaction between 
MB, a reversible monoamine oxidase inhibitor and his antidepressants overdose. We report MB 
pharmacokinetic data with a calculated half-life of 38 hours. 
 
Introduction 
 
Poisoning induced vasoplegic shock caused by the loss of vascular smooth muscle tone and severe 
vasodilatation can progress to multi-organ failure and mortality up to 25%, especially if it is resistant to 
catecholamine treatment and lasts longer than 48 hours.(1) Methylene blue (MB) has been used for 
the management of distributive shock such as sepsis and toxic vasoplegic shock.(1) While MB has 
been reported to cause SS in surgical cases where it was used as a surgical dye, there have been no 
reported cases of SS in association with its use in poisoning related vasoplegic shock. We report a 
case of severe SS in an overdosed patient treated with MB to manage catecholamine resistant 
vasoplegic shock and calculated MB pharmacokinetic data. 
 
Case details 
 
A 70 kg 15-year-old male with a background history of essential hypertension and major depression 
presented to the Emergency Department 1.5 hours post ingestion of a large mixed overdose of his 
own medications. Empty packets suggested ingestion of quetiapine slow release 1.5 g, quetiapine 
immediate release 12 g, desvenlafaxine moderate release 5.6 g, venlafaxine 1050 mg, amlodipine 
290 mg, ramipril 100 mg, fluoxetine 560 mg and promethazine 500 mg. 
 
On arrival at the Emergency Department, he had a systolic blood pressure of 80mmHg, pulse of 130 
bpm and Glasgow Coma Score of 8 (Figure 1). He was resuscitated with 3.5 L of crystalloid fluid, 10 
ml 10% calcium gluconate and intubated. A dose of activated charcoal (50g) was administered. Over 
the next hour he required rapidly escalating boluses of metaraminol (total dose: 1.5 mg) to maintain a 
mean arterial pressure (MAP) of 50 mmHg. He was then commenced on noradrenaline, followed by 
vasopressin. Doses quickly escalated to 2 mcg/kg/min noradrenaline and 7 u/h of vasopressin, with 
no improvement. Bedside transthoracic echocardiogram showed a hyperdynamic heart with good 
global contractility. 
 
Due to persistent hypotension with MAP of 48 mm Hg, a bolus of MB 1.5 mg/kg was given at 6.5h 
post overdose, followed by an infusion of 1.5mg/kg/h for 12 h and then 1 mg/kg/h for a further 12 h. 
The MAP improved in less than 30 minutes to 70 mmHg. Within 60 minutes of MB infusion, his BP 
increased from 65/40 mm Hg to 120/45 mm Hg. A PiCCO (Pulse index Contour Continuous Cardiac 
Output) catheter was inserted post commencement of MB infusion. This showed a cardiac output of 
8L/min and systemic vascular resistance (SVR) of 300 dyn.s.cm-5 (N:700-1600). His haemodynamic 
status stabilised and vasopressin was weaned to 2.4 u/h within 3 hours and noradrenaline to 0.6 
mcg/kg/min within 1 hour. He developed transient oliguria and creatinine rose to 130 μmol/L (N: 60- 
100μmol/L) but subsequently improved. 
 
Twelve hours post overdose the patient developed fixed dilated pupils measuring 6 mm and an 
increasing temperature to over 38.5°C. A CT brain showed no acute abnormality. He was paralysed, 
given levetiracetam (1g) and actively cooled. He developed progressive hyperthermia and increasing 
rigidity in the lower limbs with sustained ankle clonus. This progressed to chest and abdominal wall 
rigidity making ventilation difficult. Electroencephalography confirmed there was no seizure activity. 
He was diagnosed with severe serotonin syndrome(SS) and required active cooling and ongoing 
paralysis with rocuronium infusion for five days post overdose. He met the Hunter Criteria for SS with 
fever, autonomic instability, severe rigidity and sustained ankle clonus.(2) He developed ventilator 
acquired pneumonia, was extubated on day 7 and made a complete recovery. 
Plasma quetiapine, amlodipine and MB concentrations were measured using liquid chromatography 
mass spectrophotometry (LCMS). Plasma quetiapine concentrations were 7.1 and 3 mg/L 
(therapeutic range: 0.1-1 mg/L) at 2 and 5 h post ingestion respectively. Amlodipine concentrations 
peaked at 84.5 μg/L (N: 5-18 μg/L) 22 h post ingestion, with a calculated half-life of 80 h. This is 
longer than the reported half-life of 35-65 h in therapeutic doses. This could be partly explained by 
erratic gut absorption as a result of the anti-muscarinic effect of quetiapine. Methylene blue 
concentrations peaked at 218 μg/L. The MB plasma concentration time profiles, fitted to a one 
compartment pharmacokinetic model by nonlinear regression (Scientist: Micromath, Missouri), were 
well described (Figure 2) and had a calculated elimination half-life of 37.6 h (Table 1). This half-life 
falls within the range of half-lives of 7.7 to 48.3h for an intravenous MB dose of 50 mg in 16 healthy 
volunteers (Figure 2).(3) 
 
Discussion 
 
We present a case of massive overdose of multiple vasodilating agents including amlodipine, Ramipril 
and quetiapine resulting in profound vasoplegia. Vasoplegia is generally defined by haemodynamic 
criteria which include mean arterial pressure < 50 mm Hg, systemic vascular resistance < 800 
dynes.s.cm-5 and cardiac index > 2.5 L/in/m2. There are case reports of severe hypotension following 
overdoses of amlodipine and angiotensin antagonists.(4) This increased toxicity is reported to be the 
result of the synergistic vasodilator effect of calcium channel antagonist(5), nitric oxide production and 
inhibition of angiotensin converting enzymes.(6) Quetiapine causes vasodilation mediated by alpha-1- 
adrenoreceptor and has H1-histamine receptor antagonist effect. Our patient has a peak serum 
concentration of 7.1 mg/l, is comparable with other severely poisoned quetiapine patients.(7) 
 
Methylene blue (MB) has been used for the management of methaemoglobinaemia, a second line 
agent for the management of septic, anaphylactic and toxic vasoplegic shock(1) or post cardiac 
surgery. Side effects associated with its use include dyspnoea, tremors, vomiting, blue discoloration 
of skin and acute haemolytic anaemia. MB causes an increase in SVR and reduce catecholamine 
requirements,(8) by inhibiting guanylate cyclase, resulting in less cGMP production and reduced 
endothelial smooth muscle relaxation. MB has been successfully used in vasoplegic shock caused by 
quetiapine(9) and amlodipine poisoning.(10) The dose used varied from 1-2 mg/kg bolus followed by 
an infusion 1-2 mg/kg/h. In a recent systematic review of drug induced vasoplegic shock treated with 
MB, there were just 17 reported cases.(11) Twelve patients survived and nine had haemodynamic 
improvement following MB administration. Of the 17 cases, 6 had taken amlodipine and 3 patients 
had improvement in haemodynamic status. In our case there was a convincing temporal relationship 
with improvement in blood pressure and reduction in catecholamine infusion within an hour of MB 
administration. 
 
An alternative diagnosis for the late deterioration is neuroleptic malignant syndrome (NMS) caused by 
quetiapine, an atypical neuroleptic. Neuroleptic malignant syndrome is characterised by hyperpyrexia, 
cogwheel rigidity, confusion and autonomic dysfunction but the symptoms have been reported to be 
less severe with second generation or atypical neuroleptics.(12) Quetiapine has affinity for 5-
hydroxytryptamine and dopamine receptors. There have been case reports of quetiapine induced 
neuroleptic malignant syndrome, but they were usually from therapeutic doses of quetiapine and 
associated with the concurrent use of other neuroleptic drugs.(13) NMS has not been reported after 
an acute overdose of quetiapine. In addition, this patient had severe lower limb muscle rigidity and 
sustained ankle clonus which are characteristic feature of severe SS and not NMS. 
 
MB is a reversible monoamine oxidase inhibitor and its use in cardiac surgery and peri-operatively for 
diagnostic purposes has been associated with SS.(14, 15) This happened in normal patients taking 
therapeutic doses of either a selective serotonin reuptake inhibitor (SSRI) or selective noradrenaline 
reuptake inhibitors (SNRI) who received 1-2 mg/kg intravenous MB prior to surgery, developed mild to 
moderate SS.(15) Moreover, this reaction can be fatal, with one case report of a 75 year old patient 
on therapeutic doses of venlafaxine, given 1 g (9mg/kg) intravenous MB prior to surgery, developed 
severe SS and died.(14) MB is a potent, reversible monoamine oxidase (MAO-A) inhibitor and has an 
active metabolite (azure B) which is thought to be 10 times more potent as an MAO-A inhibitor. In our 
case, it is likely that severe SS was precipitated by high doses of MB in conjunction with an overdose 
of venlafaxine, desvenlafaxine and fluoxetine. The delayed onset of severe toxicity may reflect 
delayed central nervous system penetration or that the metabolite concentrations peaked later. 
The prolonged effect is easily explained by the long half-lives observed for MB and expected for the 
SSRIs. Fluoxetine and its active metabolite norfluoxetine are known to have half-lives of 4-6 days and 
16 days respectively. 
 
Our patient had a half-life of MB (37.6 h) that is consistent with the literature (8-48 h) and developed 
prolonged severe SS that required paralysis for 5 days. Due to the long half-life of MB seen in this 
patient perhaps bolus doses of MB (1 mg/kg) given as clinically required would have been sufficient 
and potentially reduced the severity of SS. 
 
In conclusion, this patient developed vasoplegic shock from a massive overdose of quetiapine, 
amlodipine and ramipril that was resistant to maximal dose of vasopressors. He was successfully 
managed with MB but this was complicated by delayed onset of persistent severe SS due to the 
interaction with SSRI (fluoxetine) and SNRI (venlafaxine and desvenlafaxine) agents. 
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Table 1. Constructed pharmacokinetic data of Methylene Blue from the patient based on a one 
compartment model. CL: clearance; V: volume of distribution; Kel: elimination rate constant; 
t1/2: Half-life; SE (CV%): standard error (coefficient of variation%). 
Parameter Final Estimate SE (CV%) Confidence interval 
(95%) 
CL (L/h) 76.44 3.94 68.7 – 84.18  
V (L) 4152 5.983 3513 – 4791 
kel (h-1) 0.01841 5.194 0.001595 – 0.02087 
t1/2 (h) 37.65 5.194 32.62 – 42.68  
 
  
